Viral Infections Market Reach $117.6 Billion Globally by 2021 – MarketIntelReports

Viral Infections Market: huge investment by Medical companies from R&D for drugs.
Viral Infections Market: high demand for treatment and drugs in Asia Pacific through 2021

Viruses are infectious particles comprising a nucleic acid core – consisting of either DNA or RNA – and a protein coat known as a capsid. Infections attributable to viral pathogens are transmitted, directly or indirectly, from one person to another or from animal to human. Every year millions of people die because of these viral infections. There is high scope for R&D for development of treatment in the Viral Infections Market.

Scope and Regional forecast of the Viral Infections Market:

The Global Viral Infections Market was valued at $74.0 billion in 2014, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 6.8%, reaching $117.6 billion in 2021. Key drivers of this growth will be the expanding treatment population and uptake of recently approved highly priced antiviral agents, as well as promising late-stage candidates that are expected to be priced highly.

North America leads the Viral Infections Market with high capital expenditure for research and development of treatment for various viral infections. Many companies are competitively investing and researching to find effective treatment solution for HIV, hepatitis and other types of diseases caused by virus.

Asia Pacific is the largest region in the Viral Infections Market. Since, this region is highly populated; there is a high demand for viral infection treatments and drugs in the region. There is huge scope for more application of new techniques and therapies through 2021.

Europe his expected to witness high demand for treatment in the Viral Infections Market. Viral infections are more complicated than bacterial infection, but bacterial infection symptoms are similar to symptoms by virus.

Complete research on Viral Infections Market available at–promising-new-competitors-and-expanding-treatment-population-to-offset-increased-uptake-of-generics

Segmentation and key players of the Viral Infections Market:

The Viral Infections Market is segmented into various categories by viral infection type, by treatment, by marketed products, by pipeline, by clinical trials, by assessment of key pipeline products and by geography.

By viral infection type: Human Immunodeficiency Virus (HIV), Hepatitis C Virus, Hepatitis B Virus and Influenza

By treatment: vaccines and antiviral agents

By marketed products:

Multiple indications: Viread – Gilead, Epivir/Epivir-HBV – ViiV Healthcare and Pegasys – F. Hoffmann La Roche

Human Immunodeficiency Virus (HIV): Truvada – Gilead, Atripla – Gilead, Stribild – Gilead, Tivicay – ViiV Healthcare, Triumeq – ViiV Healthcare and Genvoya – Gilead

Hepatitis C Virus (HCV): Olysio – Janssen, Sovaldi and Harvoni – Gilead and Zepatier – Merck and Co.

Hepatitis B Virus: Baraclude – Bristol-Myers Squibb

Influenza Virus: Tamiflu – Roche

By pipeline: pipeline products by stage of development and molecule type, pipeline products by molecular target

By clinical trials: clinical trial failure rates, clinical trial duration, clinical trial size and cumulative clinical trial size

By assessment of key pipeline products: Sofosbuvir in Combination with Velpatasvir – Gilead, Tenofovir alafenamide fumarate – Gilead, Descovy – Gilead, Cobicistat, darunavir, emtricitabine and TAF – Johnson & Johnson, Beclabuvir hydrochloride – Bristol-Myers Squibb and V-212 – Merck

By geography: North America, South America, Europe, Asia Pacific and ROW

Order a copy of Viral Infections Market report @  

The key players in the Viral Infections Market are as follows:

  • Johnson & Johnson
  • Bristol-Myers Squibb
  • Merck & Co.
  • Gilead
  • Roche

The Viral Infections Market is a rapidly growing market with high potential in the global market. High investment for R&D and drug production is made by many companies and pharmaceuticals across the globe.

The Viral Infections Market is expected to witness high growth owing to the increasing population affected with viruses and high demand for drugs through 2021.

Check research sample here

On a related note, another research on

Ebola Viral Infections – Pipeline Review, H1 2016 @–pipeline-review-h1-2016

Epstein-Barr Viral Infections Global Clinical Trials Review, H2, 2015 @

About Us:

MarketIntelReports (MIR) aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.

MarketIntelReports currently has more than 10,000 plus titles and 35+ publishers on our platform and growing consistently to fill the “Global Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.

Media Contact
Company Name: MarketIntelReports
Contact Person: Mayur S.
Email: Send Email
Phone: 1-302-261-5343
Address:2711 Centerville Road, Suite 400
City: Wilmington
State: Delaware
Country: United States